Bank of America
SPRY icon

Bank of America’s ARS Pharmaceuticals SPRY Stock Holding History

Bank of America’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.29M Sell
285,728
-196,356
-41% -$1.88M ﹤0.01% 4028
2025
Q4 		$5.62M Buy
482,084
+210,058
+77% +$2.04M ﹤0.01% 3297
2025
Q3 		$2.73M Sell
272,026
-53,326
-16% -$765K ﹤0.01% 4542
2025
Q2 		$5.68M Sell
325,352
-119,351
-27% -$1.72M ﹤0.01% 3766
2025
Q1 		$5.59M Buy
444,703
+283,745
+176% +$3.41M ﹤0.01% 3695
2024
Q4 		$1.7M Buy
160,958
+48,094
+43% +$674K ﹤0.01% 4592
2024
Q3 		$1.64M Buy
112,864
+4,790
+4% +$57K ﹤0.01% 4711
2024
Q2 		$920K Buy
108,074
+26,495
+32% +$235K ﹤0.01% 4954
2024
Q1 		$834K Sell
81,579
-17,019
-17% -$127K ﹤0.01% 5048
2023
Q4 		$540K Buy
98,598
+42,154
+75% +$185K ﹤0.01% 5434
2023
Q3 		$213K Buy
56,444
+30,018
+114% +$197K ﹤0.01% 5870
2023
Q2 		$177K Buy
26,426
+1,926
+8% +$12.9K ﹤0.01% 5917
2023
Q1 		$159K Buy
24,500
+11,261
+85% +$86.5K ﹤0.01% 6037
2022
Q4 		$113K Buy
13,239
+2,785
+27% +$18.1K ﹤0.01% 6184
2022
Q3 		$55K Sell
10,454
-232,987
-96% -$1.15M ﹤0.01% 6635
2022
Q2 		$1.03M Sell
243,441
-20,425
-8% -$71.2K ﹤0.01% 4879
2022
Q1 		$926K Buy
263,866
+240,090
+1,010% +$1.05M ﹤0.01% 5353
2021
Q4 		$158K Buy
23,776
+20,490
+624% +$167K ﹤0.01% 6632
2021
Q3 		$32K Sell
3,286
-29,932
-90% -$738K ﹤0.01% 7238
2021
Q2 		$1.03M Buy
33,218
+6,459
+24% +$207K ﹤0.01% 4884
2021
Q1 		$1.17M Buy
+26,759
New +$1.27M ﹤0.01% 4703

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America's SPRY Position: Q1 2026 in Review

Bank of America reduced its ARS Pharmaceuticals (SPRY) stake by 41% in Q1 2026, selling an estimated $1.88M and leaving 285,728 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4028.

Bank of America first reported a position in SPRY in Q1 2021 and has held it in 21 quarters since. The position peaked at $5.68M in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

  • Bank of America held 285,728 shares of ARS Pharmaceuticals worth $2.29M as of Q1 2026.
  • Bank of America sold 196,356 ARS Pharmaceuticals shares in Q1 2026, an estimated $1.88M.
  • ARS Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4028 holding.
  • Bank of America first reported a position in ARS Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • Bank of America's ARS Pharmaceuticals position peaked at $5.68M in Q2 2025.
  • 202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.